Amicus Therapeutics initiates trial of AT2220 in Pompe disease
Amicus Therapeutics has initiated a Phase 2 clinical trial of AT2220, for the treatment of Pompe disease.
Researchers from Boston University School of Medicine have discovered a new gene therapy that may prevent the progression of emphysema.